Inventor · disambiguated record
Armin Ehninger
Also filed as: EHNINGER ARMIN
6 granted patents·5 pending applications·12 citations·filing 2015–2023
77Inventor score
Top patents by PatentIndex Score
11 records- 0187US10072079B2Isolated human mesenchymal stem cell expressing a bispecific antibody that binds CD33 and CD3GEMOAB MONOCLONALS GMBH·Filed 2015·Granted Sep 11, 2018·5 cites·5 claims
- 0282US10766943B2Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disordersGEMOAB MONOCLONALS GMBH·Filed 2019·Granted Sep 8, 2020·1 cites·9 claims
- 0381US11560426B2Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disordersAVENCELL EUROPE GMBH·Filed 2018·Granted Jan 24, 2023·3 cites·12 claims
- 0481US10611814B2Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disordersGEMOAB MONOCLONALS GMBH·Filed 2015·Granted Apr 7, 2020·2 cites·14 claims
- 0577US10941202B2Isolated human mesenchymal stem cell expressing a bispecific antibody that binds CD33 and CD3 and method of using to treat cancerGEMOAB MONOCLONALS GMBH·Filed 2018·Granted Mar 9, 2021·1 cites·13 claims
- 0669US12173063B2Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer, infections and autoimmune disordersAVENCELL EUROPE GMBH·Filed 2022·Granted Dec 24, 2024·0 cites·14 claims
- 0765US2021284729A1Genetic modified pluri- or multipotent stem cells and uses thereofGEMOAB MONOCLONALS GMBH·Filed 2021·Application pending·0 cites
- 0860US2021206828A9Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disordersGEMOAB MONOCLONALS GMBH·Filed 2020·Application pending·0 cites
- 0960US2025269025A1Targeting modules against cd123 for use in a method for stimulating a chimeric antigen receptor-mediated immune response in a mammalAVENCELL THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1049US2025302875A1TARGETING MODULES AGAINST IL13R-alpha-2 AND/OR HER2 FOR USE IN A METHOD FOR STIMULATING A CHIMERIC ANTIGEN RECEPTOR-MEDIATED IMMUNE RESPONSE IN A MAMMALAVENCELL EUROPE GMBH·Filed 2022·Application pending·0 cites
- 1148US2023183351A1A targeting module comprising pd-l1 and/or pd-l2 for use in a method for stimulating a chimeric antigen receptor mediated immune response in a mammalAVENCELL EUROPE GMBH·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Armin Ehninger files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →